Thus, the aim of this study was 1) to determine whether subcutaneous (SC) versus intravenous (IV) administration of ofatumumab or ocrelizumab alters antibody distribution in huCD20 mice; 2) to assess whether anti-CD20-mediated B-cell depletion can be detected with an indium (111In)-labelled anti-CD19 antibody; and 3) to establish how the administration route affects the efficacy of anti-CD20 mAbs in a huCD20 mouse model of MS. Here, CD19 is linked to myeloid sarcoma.